# Open-Label Extension of EryDex Study IEDAT-04-2022

> **NCT06664853** · PHASE3 · TERMINATED · sponsor: **Quince Therapeutics S.p.A.** · enrollment: 101 (actual)

## Conditions studied

- Ataxia Telangiectasia

## Interventions

- **DRUG:** Dexamethasone sodium phosphate

## Key facts

- **NCT ID:** NCT06664853
- **Lead sponsor:** Quince Therapeutics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-11
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 101 (ACTUAL)
- **Why stopped:** eDSP development discontinued
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664853, "Open-Label Extension of EryDex Study IEDAT-04-2022". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06664853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*